Skip to content
Acetrizoic acid
Salpix (acetrizoic acid) is a small molecule pharmaceutical. Acetrizoic acid was first approved as Salpix on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Acetrizoate sodium
Tradename
Company
Number
Date
Products
SALPIXJohnson & JohnsonN-009008 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
— V08: Contrast media
— V08A: X-ray contrast media, iodinated
— V08AA: Watersoluble, nephrotropic, high osmolar x-ray contrast media
— V08AA07: Acetrizoic acid
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameACETRIZOIC ACID
INNsodium acetrizoate
Description
Acetrizoic acid is an aminobenzoic acid.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(=O)Nc1c(I)cc(I)c(C(=O)O)c1I
Identifiers
PDB—
CAS-ID85-36-9
RxCUI—
ChEMBL IDCHEMBL1201327
ChEBI ID34521
PubChem CID6806
DrugBankDB09347
UNII ID5GF4B2I1DD (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 65 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details